Grant: Collaborative Research and Development Grants
McMaster University
$80,000.00
Development of biomarkers for efficient identification of human fungal pathogens
FY 2017-18
Summary
Innovative methods for rapid and accurate diagnosis are urgently needed for the effective treatment of one of the biggest threats to human health: fungal pathogens. Fungal infections are rampant and drug resistance is increasingly problematic. However, the current methods used in the diagnosis of fungal infections and the determination their susceptibilities to antifungal drugs are rudimentary and there is a significant time lag, usually days and sometimes weeks, in providing the best treatment options to patients.We will develop rapid and accurate molecular diagnosis methods that can identify not only a wide range of fungal pathogens but also detect clinically significant resistance mechanisms. To achieve this goal, we will take an integrative approach to systematically analyze the taxonomy, population genetics and genomics literature to identify the patterns of DNA sequence variation within and between fungal pathogen species, populations, and strains. From these comparisons, we will develop highly sensitive and specific DNA signature sequences for species, populations, and in certain cases, strains. Because clinical microbiology laboratories differ in their setup and capabilities in running DNA-based molecular diagnosis, whenever possible, together with our industrial partners, we will test and develop the biomarkers for different platforms, including fluorescent in situ hybridization (FISH), classical PCR, real-time PCR, and isothermal amplifications. The biomarkers and methods developed here will be further evaluated by our industrial partner to assess their commercial potential as molecular diagnosis kits and/or as service platforms to healthcare providers. At present, there is almost no Canadian presence in commercial medical fungi diagnosis or in the development of molecular biomarkers for rapid and accurate diagnosis of human fungal pathogens.
Program
Collaborative Research and Development Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
474638-2014
Name nom
Xu, Jianping
Department département
Biology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2014
Award amount
80000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5205
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Mycology
Research subject fr
Mycologie
Partie
3
Nb partie
3
Application title
Development of biomarkers for efficient identification of human fungal pathogens
Keyword
NSERC
Application summary
Innovative methods for rapid and accurate diagnosis are urgently needed for the effective treatment of one of the biggest threats to human health: fungal pathogens. Fungal infections are rampant and drug resistance is increasingly problematic. However, the current methods used in the diagnosis of fungal infections and the determination their susceptibilities to antifungal drugs are rudimentary and there is a significant time lag, usually days and sometimes weeks, in providing the best treatment options to patients.We will develop rapid and accurate molecular diagnosis methods that can identify not only a wide range of fungal pathogens but also detect clinically significant resistance mechanisms. To achieve this goal, we will take an integrative approach to systematically analyze the taxonomy, population genetics and genomics literature to identify the patterns of DNA sequence variation within and between fungal pathogen species, populations, and strains. From these comparisons, we will develop highly sensitive and specific DNA signature sequences for species, populations, and in certain cases, strains. Because clinical microbiology laboratories differ in their setup and capabilities in running DNA-based molecular diagnosis, whenever possible, together with our industrial partners, we will test and develop the biomarkers for different platforms, including fluorescent in situ hybridization (FISH), classical PCR, real-time PCR, and isothermal amplifications. The biomarkers and methods developed here will be further evaluated by our industrial partner to assess their commercial potential as molecular diagnosis kits and/or as service platforms to healthcare providers. At present, there is almost no Canadian presence in commercial medical fungi diagnosis or in the development of molecular biomarkers for rapid and accurate diagnosis of human fungal pathogens.